Arrow LionHeart
This article was originally published in The Gray Sheet
Executive Summary
Preliminary data review of 25 patients implanted with the left ventricular assist system shows the device is associated with tangible improvements in quality of life and has yet to fail or cause infection, according to notified body TUV Munich. However, TUV believes 10-15 patients will need to be added over the next six months to compare Arrow's trial to Thoratec's seminal 67-patient REMATCH trial of the HeartMate VE, which is now considered the benchmark for all future LVAS trials (1"The Gray Sheet" April 15, 2002, p. 17). The LVAS system will probably receive its European CE mark in early 2003, instead of June 2002, as the company had first predicted, due to the change in trial protocol (2"The Gray Sheet" March 11, 2002, p. 16)...
You may also be interested in...
CHF Device Trial Endpoints Clarification From FDA Requested
Thoratec's REMATCH trial of the HeartMate VE left ventricular assist device, designed to demonstrate improved survival versus optimal medical management, will not be generalizable to most congestive heart failure device trials, according to Mehmet Oz, MD, Columbia University
Arrow LionHeart LVAD Trial Progress Supports 13% Stock Gain In February
Continued clinical progress in the development of Arrow's LionHeart left ventricular assist device (LVAD) as a destination therapy helped sustain a 13.2% advance in the firm's stock price in February to $45.73
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.